Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir
Archives of Clinical Infectious Diseases · 23.02.2026 · 21 (1)
DOI: 10.5812/archcid-158027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Infectious Diseases, online erschienen am 23.02.2026. Verfasst von Mohsen Aliakbarian und 8 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Universal prophylaxis and preemptive therapy are established strategies to prevent cytomegalovirus (CMV) after liver transplantation, yet their real-world comparative performance varies by center and risk mix.
Methods
We conducted a single-center retrospective cohort of consecutive adult recipients transplanted from 2013 - 2021 in Mashhad, Iran. Exposure was the CMV-prevention strategy received (universal valganciclovir prophylaxis vs preemptive PCR-based monitoring). Primary outcomes were CMV viremia (PCR-confirmed) and CMV disease (clinical/histologic). Secondary outcomes were late-onset CMV (> 100 days post-transplant), acute rejection, and mortality. Multivariable logistic regression (and Cox proportional hazards where event dates were available) adjusted for calendar era, donor/recipient serostatus (D/R), immunosuppression regimen, monitoring protocol, age, and sex.
Results
Among 475 recipients (universal valganciclovir: 170; preemptive monitoring: 305), CMV viremia occurred in 10/170 (5.9%) vs 18/305 (5.9%) (P = 0.993). Among the 28 infected patients, 23 (82.1%) were male. Onset timing was < 1 month in 6 (21.4%), 1 - 3 months in 9 (32.1%), and > 6 months in 13 (46.4%), indicating late-onset (> 3 months) in 22/28 (78.6%) overall.
Conclusions
In this cohort, universal prophylaxis and preemptive monitoring showed no significant adjusted differences in CMV infection or disease. Given era effects and center-specific practices, policy selection should consider D/R risk, monitoring logistics, and late-onset CMV risk. Multicenter studies are warranted.
Zitieren
APA
Aliakbarian, M., Majidianfar, F., Kakhki, S. S. A., Javanshir, S., Khodashahi, M., Rezayat, K. A., Moghadam, M. D., Rahbardar, M. G., & Khodashahi, R. (2026). Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir. Archives of Clinical Infectious Diseases, 21(1). https://doi.org/10.5812/archcid-158027
Vancouver
Aliakbarian M, Majidianfar F, Kakhki SSA, Javanshir S, Khodashahi M, Rezayat KA, et al. Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir. Archives of Clinical Infectious Diseases. 2026;21(1). doi:10.5812/archcid-158027
BibTeX
@article{Aliakbarian2026,
author = {Aliakbarian, Mohsen and Majidianfar, Faezeh and Kakhki, Seyed Sajjad Alavi and Javanshir, Saeed and Khodashahi, Mandana and Rezayat, Kambiz Akhavan and Moghadam, Maliheh Dadgar and Rahbardar, Mahboobeh Ghasemzadeh and Khodashahi, Rozita},
title = {Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir},
journal = {Archives of Clinical Infectious Diseases},
year = {2026},
volume = {21},
number = {1},
doi = {10.5812/archcid-158027}
}
EUVIMED